CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48 enrolled
Drug / intervention
Indego Exoskeletondevice
Likely dose
Indego exoskeleton training: five training sessions over two weeksAI-extracted
Key inclusion· 10
  • History of one sided ischemic or hemorrhagic stroke with resultant hemiparesis
  • Manual Muscle Test (MMT) 4/5 in at least upper extremity
  • No other brain abnormalities or neurological diseases/disorders
  • Only one stroke diagnosis (not multiple strokes)
Key exclusion· 5
  • Multiple prior strokes
  • Pregnancy
  • Colostomy bag
  • Uncontrolled or untreated hypertension or hypotension

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03054064
NCT03054064N/ACompleted

Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA

Parker Hannifin Corporation·interventional·Posted Feb 15, 2017·Updated Apr 7, 2020

In Brief

A clinical study evaluating Indego Exoskeleton for Cerebrovascular Accident (CVA) and 2 related conditions. Completed, enrolled 48 participants across 7 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of the Indego exoskeleton as a gait training tool for individuals with hemiplegia due to Cerebrovascular Accident (CVA).

Study Details

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 15, 2017
Enrollment StartFeb 21, 2017
Primary CompletionDec 28, 2017
Study CompletionJan 17, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.4 years ago

Interventions

Indego Exoskeletondevice

Six study sessions including five Indego training sessions over two weeks.